YD Bio Stock
YD Bio Limited Ordinary Shares
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Taiwan
- CEO
- Ethan Shen
- Employees
- 14
- Market cap
- $419 M
- IPO
- 29/08/2025
YD Bio Limited, a biopharmaceutical company, focuses on regulated diagnostics, life science clinical services, and healthcare product commercialization in the United States and Taiwan. The company offers eye disease treatment products, 3D LensMate Artificial Tears, a natural tear-mimicking lubricant that moisturizes…
YD Bio stock: price history
1D
-12.2%
1W
-12.0%
1M
+60.0%
6M
+8.8%
YTD
-51.4%
1Y
-68.6%
2Y
–
5Y
–
10Y
–
Ask the agents about YD Bio
YD Bio stock metrics
P/E
-49.33
P/B
-138.31
EV/EBITDA
-51.01
RETURN ON EQUITY
0.0%
NET MARGIN
0.0%
DEBT/EQUITY
0
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
2.0%
FLOAT SHARES
1,427,004
AVG. DAILY VOLUME (30D)
502,670
Insider transactions (SEC)
Lu Shao-Ta
Chang Kochi
Shen Ethan PhD
Shen Ethan PhD
Shen Ethan PhD
Institutional holders
Comparable stocks
Frequently asked questions about YD Bio stock
What does YD Bio do?
YD Bio Limited Ordinary Shares is a company in the Healthcare sector, Biotechnology industry, headquartered in Taiwan.
The CEO is Ethan Shen, the company employs around 14 people.
The IPO was on 29/08/2025; the stock trades on NASDAQ under the ticker YDES.
Does YD Bio pay a dividend?
No, YD Bio currently does not pay a dividend.
Which stocks are comparable to YD Bio?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, argenx, Revolution Medicines, BeOne Medicines, Incyte and Genmab A/S.
How can I get YD Bio stock analyzed?
Clicking "Analyze stock" lets five strategies assess YD Bio against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.